New medications for atopic dermatitis (eczema) have emerged. This course reviews new biologics and Janus kinase (JAK) inhibitors and gives you the information you need to make the right treatment decisions and impact patient adherence.

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Review recent pathophysiological findings in Atopic Dermatitis (AD) that have produced new therapeutic targets
2. Explain the mechanisms of action and clinical profiles of new and emerging targeted systemic agents for the long-term treatment of AD in adult and pediatric patients
3. Discuss how adherence barriers play a role in long-term treatment decision-making for adults and pediatric patients with AD
4. Review comorbidity considerations for treatment decision-making based on the most recent guidance for AD
5. Recommend pharmacologic and nonpharmacologic therapy for a patient with AD 

Geoff Wall, PharmD, BCPS FCCP
Professor of Pharmacy Practice
Drake University

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: January 1, 2023
Planned Expiration Date: January 1, 2026

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

RV1-10.23